RESUMO
Bronchiectasis in adults is a chronic disorder associated with poor quality of life and frequent exacerbations in many patients. There have been no previous international guidelines.The European Respiratory Society guidelines for the management of adult bronchiectasis describe the appropriate investigation and treatment strategies determined by a systematic review of the literature.A multidisciplinary group representing respiratory medicine, microbiology, physiotherapy, thoracic surgery, primary care, methodology and patients considered the most relevant clinical questions (for both clinicians and patients) related to management of bronchiectasis. Nine key clinical questions were generated and a systematic review was conducted to identify published systematic reviews, randomised clinical trials and observational studies that answered these questions. We used the GRADE approach to define the quality of the evidence and the level of recommendations. The resulting guideline addresses the investigation of underlying causes of bronchiectasis, treatment of exacerbations, pathogen eradication, long term antibiotic treatment, anti-inflammatories, mucoactive drugs, bronchodilators, surgical treatment and respiratory physiotherapy.These recommendations can be used to benchmark quality of care for people with bronchiectasis across Europe and to improve outcomes.
Assuntos
Humanos , Antibacterianos/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Bronquiectasia/tratamento farmacológico , Bronquiectasia/cirurgia , Broncodilatadores/uso terapêutico , Modalidades de FisioterapiaRESUMO
INTRODUCTION: In community-acquired pneumonia, severity assessment tools, such as CRB65, CURB65 and Pneumonia Severity Index (PSI), have been promoted to increase the proportion of patients treated in the community. The prognostic accuracy of these scores is established in hospitalized patients, but less is known about their use in out-patients. We aimed to study the accuracy of these severity tools to predict mortality in patients managed as out-patients. METHODS: We performed a systematic review and meta-analysis according to MOOSE guidelines. From 1980 to 2010, we identified 13 studies reporting prognostic information for the CRB65, CURB65 and PSI severity scores in out-patients (either exclusively managed in the community or discharged from an emergency department <24 h after admission). Two reviewers independently collected data and assessed study quality. Performance characteristics across the studies were pooled using a random-effects model. Relationships between sensitivity and specificity were plotted using summary receiver operator characteristic curves (sROC). RESULTS: Out-patient mortality ranged from 0% to 3.5%. Four studies were identified for CRB65, 2 for CURB65 and 10 for PSI. Mortality was low for out-patients in the low-risk CRB65 classes [CRB65 0 or 1: mortality occurred in 3 of 1494 patients (0.2%)] but higher in CRB65 Groups 2-4 [mortality 13 of 154 patients (8.4%)]. Similarly, mortality was low in PSI Classes I-III [mortality 8 of 3655 patients (0.2%)] managed as out-patients but higher in Classes IV and V [mortality 32 of 317 patients (10.1%)]. CRB65 showed pooled sensitivity of 81% (54-96%), pooled specificity of 91% (90-93%) and the area under the sROC was 0.91 [standard error (SE) 0.05]. For PSI, pooled sensitivity was 92% (64-100%), pooled specificity was 90% (89-91%) and area under the sROC was 0.92 (SE 0.03). There were insufficient studies to analyse CURB65. CONCLUSION: The limited data available suggest that CRB65 and PSI can identify groups of patients at low risk of mortality that can be safely managed in the community.
Assuntos
Pneumonia/diagnóstico , Índice de Gravidade de Doença , Serviços de Saúde Comunitária , Infecções Comunitárias Adquiridas/diagnóstico , Infecções Comunitárias Adquiridas/mortalidade , Infecções Comunitárias Adquiridas/terapia , Humanos , Pneumonia/mortalidade , Pneumonia/terapia , PrognósticoRESUMO
BACKGROUND: Biomarkers and clinical prediction rules have been proposed for severity assessment in acute pulmonary embolism (PE). AIM: The aim of this study was to compare biomarkers with the PE Severity Index (PESI), a validated scoring system for predicting 30-day mortality and to determine if addition of biomarkers to PESI would improve its predictive accuracy. STUDY DESIGN AND METHODS: We conducted a retrospective analysis of normotensive patients admitted with PE confirmed by CT pulmonary angiogram, to three teaching hospitals between January 2005 and July 2007. All patients had admission levels of D-dimer and Troponin I and calculation of PESI score on admission. The outcome of interest was 30-day mortality. RESULTS: There were 411 patients included in the study. Patients who died had higher levels of D-dimer (median 2947 ng/ml vs. 1464 ng/ml; P=0.02), Troponin (57.1% positive vs. 13.8%; P<0.0001) and higher PESI scores [median 109 vs. 83; P<0.0001], compared to survivors. PESI had superior accuracy for predicting 30-day mortality than a combination of Troponin and D-dimer (AUC 0.80 vs. 0.75). Addition of Troponin to PESI further improved the predictive value of the score (AUC 0.85 for vs. AUC 0.80 for PESI alone). CONCLUSION: Biomarkers and clinical prediction rules predict outcome in acute PE. Addition of troponin to the PESI scoring system improves the predictive value for 30-day mortality and may be useful for guiding initial management of patients presenting with PE.
Assuntos
Embolia Pulmonar/diagnóstico , Índice de Gravidade de Doença , Idoso , Biomarcadores/sangue , Pressão Sanguínea/fisiologia , Métodos Epidemiológicos , Feminino , Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Embolia Pulmonar/mortalidade , Embolia Pulmonar/fisiopatologia , Escócia/epidemiologia , Tomografia Computadorizada por Raios X , Troponina I/sangueRESUMO
The aim of this study was to determine whether there is superior diagnostic accuracy for the detection and exclusion of bronchiectasis using 16-slice CT of the chest (1 mm) compared with conventional high-resolution CT (HRCT) of the chest (10 mm). A prospective study was carried out in patients who were referred for chest CT by a chest physician for the investigation of bronchiectasis over a 1-year period. All scans were performed using a 16-slice CT scanner. In addition to contiguous 1 mm slices, conventional HRCT images (1 mm slice every 10 mm) were prepared. Both datasets were dual read. There were 53 patients with a median age of 62 years (range, 51.5-71.5 years), comprising 14 males and 39 females. 10 of 53 scans had no bronchiectasis in either dataset. 36 patients had bronchiectasis diagnosed on both HRCT and 1 mm scans. Two patients had tubular bronchiectasis on the HRCT scans, which was not confirmed on the 1 mm scans. Five patients had confirmed tubular bronchiectasis on the 1 mm scans, which was not identified on HRCT scans. 40 extra lobes demonstrated bronchiectasis on the 1 mm vs the HRCT scans; of these, half were labelled as definite bronchiectasis on the 1 mm scan. There was a 32% increased confidence with the 1 mm scans compared with conventional HRCT of the chest in the diagnosis of bronchiectasis (p < 0.001). In conclusion, there is improved diagnostic accuracy and confidence for diagnosis and exclusion of bronchiectasis using 16-slice chest CT (1 mm cuts) compared with conventional HRCT of the chest.
Assuntos
Bronquiectasia/diagnóstico por imagem , Tomografia Computadorizada por Raios X/métodos , Idoso , Bronquiectasia/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Doses de Radiação , Sensibilidade e EspecificidadeRESUMO
Severity assessment is an important early step in the management of patients presenting with community-acquired pneumonia. Various pneumonia-specific scores, generic sepsis scores and predictive biomarkers have been proposed as tools to aid clinicians in key management decisions. However, there is no uniform agreement about the optimum severity assessment tool to use. This review provides a summary of current evidence surrounding severity assessment in adult patients presenting with community-acquired pneumonia.
Assuntos
Pneumonia/diagnóstico , Índice de Gravidade de Doença , Adulto , Idoso , Idoso de 80 Anos ou mais , Área Sob a Curva , Biomarcadores , Infecções Comunitárias Adquiridas/diagnóstico , Infecções Comunitárias Adquiridas/mortalidade , Humanos , Pessoa de Meia-Idade , Pneumonia/mortalidade , Sensibilidade e EspecificidadeRESUMO
BACKGROUND: Airway inflammation, with recruitment of neutrophils to the airway lumen, results in purulent secretions and a variety of potential adverse consequences for patients with chronic bronchitis and bronchiectasis. We hypothesised that gradations of sputum colour would correlate directly with the myeloperoxidase content of sputum and with various other indicators of the activity and consequences of bronchial diseases. METHODS: To test this hypothesis, we quantified sputum colour by reference to a sensitive nine point colour chart and correlated this assessment with indices of a number of inflammatory mediators in sputum. RESULTS: The results indicate that standardised visual measurements of sputum colour correlated strongly with myeloperoxidase, interleukin 8, leucocyte elastase (both activity and total quantity), sputum volume, protein leak, and secretory leucocyte proteinase inhibitor (p<0.001 for all). In addition, there was a strong direct correlation between leucocyte elastase and both myeloperoxidase (p<0.003) and sputum volume (p<0.001), but a strong negative correlation with secretory leucocyte proteinase inhibitor (p<0.001). CONCLUSIONS: These results indicate that sputum colour graded visually relates to the activity of the underlying markers of bronchial inflammation. The results of this simple visual analysis of sputum provides guidance concerning underlying inflammation and its damaging potential. It also provides a useful scientific tool for improving the monitoring of chronic airways diseases and response to treatment.